等待開盤 01-14 09:30:00 美东时间
+0.360
+1.31%
今日重点评级关注:HC Wainwright & Co.:维持Assertio Holdings"买入"评级,目标价从3美元升至35美元;HC Wainwright & Co.:维持万达生物制药"买入"评级,目标价从20美元升至22美元
01-06 17:52
Susquehanna analyst Bascome Majors maintains Forward Air (NASDAQ:FWRD) with a Positive and raises the price target from $42 to $45.
01-05 22:07
U.S. stocks were lower, with the Dow Jones index falling more than 400 points o...
2025-11-07 01:42
Forward Air shares are trading higher. The company reported Q3 financial result...
2025-11-06 21:51
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Forward Air 2025年第三季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **整体财务表现:** - 合并EBITDA达到7800万美元,与第二季度的7700万美元基本持平 - 调整后EBITDA为7500万美元,较第二季度的7400万美元增长,同比去年同期的7600万美元略有下降 - 经营现金流为5300万美元,同比增长200万美元 - 年初至今经营现金流为6700万美元,同比大幅改善1亿美元 **分部门业绩:** - **快递货运部门**:EBITDA为3000万美元,利润率11.5%,与第二季度持平 - **Om
2025-11-06 13:03
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
2025-11-05 07:00
https://www.axios.com/pro/supply-chain-deals/2025/10/20/forward-air-auction-private-equity-strategics
2025-10-21 02:28
今日重点评级关注:韦德布什:维持Artiva Biotherapeutics"跑赢大市"评级,目标价从18美元升至23美元;巴克莱:维持Cellectis"超配"评级,目标价从4美元升至8美元
2025-10-20 10:03
Stifel analyst J. Bruce Chan maintains Forward Air (NASDAQ:FWRD) with a Buy and lowers the price target from $32 to $30.
2025-10-17 22:20
Forward Air ( ($FWRD) ) has issued an announcement. On October 10, 2025, Joseph...
2025-10-15 20:18